Redeye updates its estimates and valuation after Indutrade's Q3 2026 report.
Redeye updates its estimates and valuation after Momentum Group's Q3 2026 report.
Aktia’s Q3 looked weak on the surface, but one-offs, hedging timing effects on NII and card-switch c...
Redeye comments on Invisio’s Q3-results, which were weaker than expected, driven by somewhat soft sa...
Enviro's Q3 report contained few surprises, as most of the key events during the quarter had already...
Redeye comments on Transtema's preliminary Q3 figures, showing a solid Sweden but a sharp decline in...
Q3 hotel sales +25% yoy to € 56.5m; ex new hotels ADR up c.
Q3 review: Exceptional beat on Indra licence. Sales +97.
Bittium provided another quarter with strong sales growth driven by Defence & Security.
Redeye comments on BioInvent's Q3 2026 report, which was published together with a rights issue of a...
Redeye provides an update following Senzime’s Q3 2026 report.
Redeye is positive about CLS being selected, together with ClearPoint Neuro, as an industry partner ...
* Adj. EBITA up 21% y-o-y and 9% above ABGSCe despite weak sales * We cut ’26e/'27e/’28e adj.
* Medical growth shines; positive margin trajectory ahead * EBITA lowered by 1-% for '26e-'28e, driv...
Endomines reported new UKKO drilling results today.
Redeye updates its estimates and valuation after Sdiptech's Q3 2026 report.
Redeye provides its initial take on Boreo's Q3 2026 report, which was clearly above both our estimat...
Reported revenue growth of 56% was strong due to Lacon acquisition.
ATOSS released Q3 figures on Friday that were mixed on sales but outstanding on profitability.
123f released preliminary 9M figures that continue the earnings momentum seen in H1.